An expert gives an overview of the different treatment approaches for patients with breast cancer that has metastasized to their brain.
There are multiple ways to treat patients with breast cancer whose disease has spread to their brain, depending on the subtype of the disease, number of lesions, and more, according to Carey K. Anders, MD, a medical oncologist at Duke Cancer Center.
TRANSCRIPTION
The initial stages when patients are diagnosed, many times, we'll move forward with neurosurgical resection if there's a solitary lesion, or if the diagnosis is in question, or if there is a large space-occupying lesion that's causing the patient mass effect. Depending on whether or not neurosurgical resection is required, we then typically go to radiation therapy. I think that landscape may be changing in the future as our systemic therapies continue to advance.
Traditionally, patients with a limited number of brain metastases will receive stereotactic radiosurgery to each of those lesions. If there are multiple lesions, and that number is debatable, potentially over 10, or diffuse dural-based disease, then patients will receive whole-brain radiation therapy.
Then at that point, in consultation with the medical oncologist, based on the patient's subtype and presence or absence of extra-cranial disease, we'll recommend systemic therapies that are most appropriate.
So the timing of each of these is important for each of the modalities of care to be discussed. I think there are multiple clinical trials looking at the timing and combinations, particularly of radiation therapy with system agents ongoing presently.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
September 17th 2024The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of recurrence.